Introducing Borchi® Dragon Low VOC high-performance catalyst
New offering from Milliken & Company's Borchers coating additives brand delivers outstanding drying performance
SPARTANBURG, S.C., May 29, 2025 /PRNewswire/ -- Borchers, a Milliken & Company brand and global leader in advanced coating additives, is proud to introduce Borchi® Dragon Low VOC, a high-performance catalyst designed to offer formulators a drying solution for alkyd coatings that is low in Volatile Organic Compound (VOC) content. Borchi® Dragon Low VOC can provide outstanding drying performance while aiming to meet evolving VOC regulations in solvent borne and solvent-free alkyd formulations. As a manganese-based solution, the product is also designed to be free of cobalt, which faces regulatory scrutiny in several regions.
"We are committed to delivering additive options like Borchi® Dragon Low VOC that help meet current labeling requirements and future-proof from potential regulations in final coating formulations," said Jeff Losch, vice president and coating additives business manager at Milliken. "This focus aligns with Milliken & Company's commitment to sustainability, which has earned the company a gold EcoVadis rating for three consecutive years."
Borchi® Dragon Low VOC contains only 2% VOC content based on ASTM D2369 standards and can help formulators reduce VOCs without sacrificing drying speed, even in challenging ambient conditions. Additionally, the catalyst offers a higher flash point (enabling safer handling), reduced yellowing, and better hardness when compared to low-VOC alternative driers. Borchi® Dragon Low VOC is up to 92% biobased carbon, as determined by ASTM D6866-24 B standards.
VOCs can be released from paint in room-temperature conditions even after the paint has dried. Governments worldwide, including those in the United States and European Union, have implemented regulations to lower VOC levels in coatings to help protect public health.
Traditionally, cobalt driers are added to alkyd formulations to accelerate cure times. However, the use of cobalt compounds in coatings has also faced regulatory scrutiny due to health toxicity concerns, being classified as a Category 1B carcinogen in the European Union and currently under evaluation by the U.S. Environmental Protection Agency (EPA).
Borchi® Dragon Low VOC is an excellent addition to Borchers' comprehensive range of cobalt-free high-performance catalysts, which includes Borchi® OXY-Coat iron-based driers for a variety of alkyd formulations. Other cobalt-free solutions include the new Borchi® Phoenix accelerator that is designed to enhance drier performance in high solids and solventborne alkyd coatings.
For more information about Borchi® Dragon Low VOC and other advanced solutions, visit borchers.com.
About MillikenMilliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow's breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people's lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, flooring, chemical and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken's curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.
About BorchersBorchers, a Milliken brand, is a global leader in high-performance additives for the coatings industry. Borchers is dedicated to developing coating additives that meet evolving market demands through innovation, technical expertise, and customer-centric collaboration.
View original content to download multimedia:https://www.prnewswire.com/news-releases/introducing-borchi-dragon-low-voc-high-performance-catalyst-302468889.html
SOURCE Milliken & Company
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise Peacock as Chief Regulatory and Quality Officer, based at the Company's Oxford, UK site. With more than 35 years in the pharmaceutical industry, Louise brings extensive and highly relevant experience to Aravax having previously made key contributions to the approval of Palforzia® - the first and only FDA approved oral immunotherapy (OIT) to treat peanut allergy. Louise has held prior roles as Chief Regulatory Affairs and Quality Officer at Vaderis Therapeutics AG and Alladapt Immunotherapeutics and was Head of Pharma R&D at Nestle Health Science/Aimmune Therapeutics (acquired by Nestle Health Science in 2020) where she had broad responsibilities for global regulatory affairs across pharma products in food allergy, gastrointestinal and metabolic disorders. Whilst at Aimmune, Louise was responsible for activities supporting the development and marketing approvals for Palforzia® in the US, EU, UK and Switzerland. Louise's early career included senior positions at Abbott Laboratories, Auxilium Pharmaceuticals, Intermune and Circassia. Louise received her BSc (Hons) Pharmacology from Kings College, London and her LLB (Hons) from the University of West London. Louise Peacock, Chief Regulatory and Quality Officer of Aravax, said, 'Despite recent advances, food allergy remains an ever-growing and life-threatening problem around the world and there is a critical need for better therapies. Having followed Aravax's developments, I am convinced that PVX108 has the potential to be a life-changing alternative for patients with peanut allergy. I look forward to joining what is a world-class team and to bringing my experience to bear on the rapid further development of PVX108 and other products.' Dr Pascal Hickey, CEO of Aravax, said, 'Louise's experience in regulatory affairs in the field of food allergy is unique. It spans all the major regulatory bodies and multiple programs including the successful approval of Palforzia®. We are enormously excited that she is joining the Aravax team.' About Aravax Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax's proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body's ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications. Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax's investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper. For more information visit: For further information please contact Media – AustraliaKirrily Davis, E: kdavis@ M: +61 (0)401 220228 Media - InternationalSue Charles, Charles Consultants E: M: +44 (0)7968 726585Chris Gardner, E: Chris@ M: +44 (0)7956 031077Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
44 minutes ago
- Business Upturn
CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup
Wilmington, Del., United States: The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year. This press release features multimedia. View the full release here: LYCRA® brand and QIRA® are principal sponsors of the Global Fashion Summit: Copenhagen Edition 2025. The brands are exhibiting at the event, where they will promote bio-derived LYCRA® fiber made with QIRA®, derived from field corn, to help make fashion more sustainable. Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social. This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience. Bio-derived LYCRA® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe. 'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.' The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July. 'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry,' said Jon Veldhouse, CEO of Qore®. 'With QIRA® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.' Learn more about this renewable offering by visiting *Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc. About The LYCRA Company The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at About Qore® LLC Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit About The Global Fashion Summit Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at LYCRA® is a trademark of The LYCRA Company. QIRA® is a trademark of Qore®. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
an hour ago
- Yahoo
First Tranche offering of UAB 'Atsinaujinančios energetikos investicijos' notes under the EUR 100 million Green Bonds Programme
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW. NEW EUR 2025/2027 NOTES Closed – End Investment Company Intended for Informed Investors UAB 'Atsinaujinančios energetikos investicijos' (the 'Company') is launching its public offering of EUR 2025/2027 Notes (ISIN LT0000134439, the 'Notes'). The Notes are being issued under the EUR 100 million Green Bond Programme. The base prospectus of the programme (the 'Prospectus') was approved by the Bank of Lithuania on 27 May to the final terms of the first tranche, dated 27 May 2025 (attached), the Company is planning to issue up to EUR 65 million of nominal value Notes with maturity of 30 months to investors in Lithuania, Latvia and Estonia. Summary of the main issue terms: First tranche size: up to 65 000 000 EUR Specified denominations: EUR 100,000 and integral multiples of EUR 1,000 Interest rate: 8%, paid semi-annually Subscription period: from 28 May 2025 to 11 June 2025 2:30 pm CEST/3:30 pm Vilnius time Settlement and issue date: 13 June 2025 Maturity date: 13 December 2027 Investors wishing to submit a subscription order must contact their brokerage company. INVESTOR PRESENTATIONSManager of Closed – End Investment Company Intended for Informed Investors UAB 'Atsinaujinančios energetikos investicijos' Mantas Auruškevičius will present the offer via webcast/conference call: English-language session: 4 June 2025 at 13:00 CEST / 14:00 Vilnius time. Please register in advance to attend: Lithuanian-language session: 5 June 2025 at 9:00 CEST / 10:00 Vilnius time. Please register in advance to attend: CONTACT INFORMATIONMantas AuruškevičiusManager of Closed – End Investment Company Intended for Informed InvestorsUAB 'Atsinaujinančios energetikos investicijos' Povilas PetručionisSecurities trader at UAB FMĮ 'Orion Securities'pp@ IMPORTANT NOTICE:This notification is not for distribution to United States news agencies or for dissemination in the United States, Canada, Japan or Australia or elsewhere where such dissemination is not of this announcement and other information in connection with the securities may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such offer or invitation to acquire securities of the Company is being made by or in connection with this notification. The Prospectus is the only legally binding document containing information on the Company, the Notes and their admission to trading on the regulated market. The Prospectus is published on the website of the Company ( as well as on and of the Prospectus shall not be understood as an endorsement of the securities admitted to trading on a regulated market. The potential investors are recommended to read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with the decision to invest in the securities. Furthermore, the securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States. Further details and required documents are available at: Attachment Final terms (Series I Tranche 1) (AEI)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
